Anakinra inhibits treatment resistance due to IL-6-dependent STAT3 activation in tumor cells by inhibiting IL-1R1 signaling on pancreatic stellate cell PSCs, thereby reducing IL-6 secretion by PSCs, and enhancing chemotherapy efficacy. The gene discussed is IL6; the disease is neoplasm.